Multiple Sclerosis Headliner, MedDay’s MD1003, has flopped in its phase III trial after failing to meet its primary endpoint. This is a disastrous blow for the supposedly vision-restoring drug, which was hoped to help aid patients with Multiple sclerosis experiencing vision loss.
This was tested by the Optometrist ‘Letter’ tool (a Snellen chart), which over the course of the MD1003 should have improved the number of letters being read from a distance. This would indicate a therapeutic effect against the inflammation caused by MS-Optical neuritis when compared to a placebo. However, at the end of the 90 patient trial, the MD1003 candidate fell short with results of improved visual acuity being statistically non-significant.
Although, the drug was shown to improve mobility…so perhaps not all is lost just yet.